Form 4: Director Daphne Karydas Receives Stock Options at COMPASS

Director Daphne Karydas was granted 21,110 stock options in COMPASS Pathways plc as part of standard equity compensation.

Summary

• Director Daphne Karydas received a grant of 21,110 share options on May 27, 2026.
• The options have an exercise price of $11.85 per share.
• The options are set to expire on May 26, 2036.
• The grant vests in full on the earlier of the first anniversary of the grant or the 2027 Annual General Meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying shares relative to the $11.85 exercise price.

Future Outlook

The options vest in one year, indicating a standard retention and incentive structure for board members.

Industry Context

StockSavvy.ai notes that equity grants to non-executive directors are standard practice in the biotechnology sector to ensure board alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical compensation packages for directors of mid-cap biotechnology firms.
• The use of a one-year cliff vesting period is standard for board-level equity awards.

Stakeholder Impact

• Minor dilution impact for shareholders upon future exercise of options.

Next Steps

• Vesting of options on May 27, 2027, or the 2027 Annual General Meeting.

Key Dates

Keywords

COMPASS Pathways, CMPS, Director Compensation, Stock Options, Insider Transaction, SEC Form 4